Phase III randomized study of 4 weeks of high-dose interferon-α-2b in stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) melanoma: a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697)

Sanjiv S. Agarwala*, Sandra J. Lee, Waiki Yip, Uma N. Rao, Ahmad A. Tarhini, Gary I. Cohen, Douglas S Reintgen, Terry L. Evans, Joanna M. Brell, Mark R. Albertini, Michael B. Atkins, Shaker R. Dakhil, Robert M. Conry, Jeffrey A. Sosman, Lawrence E. Flaherty, Vernon K. Sondak, William E. Carson, Michael G. Smylie, Alberto S. Pappo, Richard F. KeffordJohn M. Kirkwood

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Phase III randomized study of 4 weeks of high-dose interferon-α-2b in stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) melanoma: a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697)'. Together they form a unique fingerprint.

Medicine & Life Sciences